HC Wainwright Predicts ImmunityBio FY2030 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) – Investment analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of ImmunityBio in a note issued to investors on Tuesday, January 20th. HC Wainwright analyst A. Maldonado forecasts that the company will earn $0.68 per share for the year. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to the consensus estimate of $31.88 million.

IBRX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. D. Boral Capital restated a “buy” rating and issued a $24.00 price objective on shares of ImmunityBio in a research note on Tuesday. Piper Sandler lifted their target price on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Jefferies Financial Group increased their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.00.

ImmunityBio Stock Up 6.8%

IBRX opened at $6.92 on Wednesday. ImmunityBio has a 52-week low of $1.83 and a 52-week high of $7.98. The company has a market cap of $6.82 billion, a P/E ratio of -16.88 and a beta of 0.03. The firm’s 50-day moving average price is $2.54 and its 200-day moving average price is $2.52.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Courier Capital LLC boosted its position in shares of ImmunityBio by 12.5% during the second quarter. Courier Capital LLC now owns 45,000 shares of the company’s stock worth $119,000 after buying an additional 5,000 shares during the period. Bell & Brown Wealth Advisors LLC lifted its stake in ImmunityBio by 6.4% during the 3rd quarter. Bell & Brown Wealth Advisors LLC now owns 82,750 shares of the company’s stock worth $204,000 after acquiring an additional 5,000 shares in the last quarter. Creative Planning boosted its holdings in ImmunityBio by 9.2% during the 2nd quarter. Creative Planning now owns 62,028 shares of the company’s stock valued at $164,000 after acquiring an additional 5,231 shares during the period. Blair William & Co. IL grew its position in ImmunityBio by 2.7% in the 2nd quarter. Blair William & Co. IL now owns 239,814 shares of the company’s stock valued at $633,000 after acquiring an additional 6,314 shares in the last quarter. Finally, Cetera Investment Advisers grew its position in ImmunityBio by 56.9% in the 2nd quarter. Cetera Investment Advisers now owns 18,551 shares of the company’s stock valued at $49,000 after acquiring an additional 6,731 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

Insider Buying and Selling at ImmunityBio

In related news, Director Barry J. Simon sold 151,967 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the transaction, the director directly owned 3,091,604 shares in the company, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total value of $187,750.00. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 226,967 shares of company stock worth $1,531,912. 69.48% of the stock is currently owned by corporate insiders.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave ImmunityBio a clear path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer, and the company plans to submit additional information within 30 days — a direct catalyst for upside. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Company press release confirmed a Type B End‑of‑Phase meeting with the FDA and outlined next steps for ANKTIVA’s sBLA, reinforcing the regulatory-path narrative that investors are rewarding. ImmunityBio Advances Regulatory Discussions with FDA
• Positive Sentiment: HC Wainwright raised its long‑term outlook (FY2030 EPS estimate to $0.68), signaling growing analyst optimism about ImmunityBio’s future earnings power (consensus had been negative).
• Positive Sentiment: At least one independent shop reaffirmed a “buy” and a high price target ($24), which may support further speculative buying interest. Benzinga
• Neutral Sentiment: The stock’s rally has extended over multiple sessions (reported as a 12‑day run in some outlets), driven in part by momentum trading and heavy volume rather than fresh clinical data. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Market coverage notes short‑sellers are under pressure as the rapid share surge forces potential covering — a technical factor that can amplify volatility but isn’t a fundamental guarantee of sustained gains. Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: Multiple outlets covered the FDA meeting and ensuing price moves; much of the market reaction reflects expectations about the timing and sufficiency of the planned resubmission analyses. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: Some analysts and commentary warn of momentum risks — advising traders to be cautious or to trim exposure amid a speculative rally and the possibility that regulatory requests could require more data or time than investors expect. Top 3 Health Care Stocks You May Want To Dump In January

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.